Literature DB >> 20814719

Expression of tenascin-C and its isoforms in the breast.

David S Guttery1, Jacqueline A Shaw, Kirsty Lloyd, J Howard Pringle, Rosemary A Walker.   

Abstract

Tenascin-C (TNC) is an extracellular matrix glycoprotein which is frequently up-regulated in a variety of pathological conditions including chronic inflammation and cancer. TNC has been implicated in the modulation of cell migration, proliferation, invasion and angiogenesis. Multiple isoforms of TNC can be generated through the alternative splicing of nine exons located in the fibronectin type III region of the molecule. The profile of isoforms expressed differs between cancers and normal breast, with the fully truncated TNC isoform being predominant in normal and benign tissues and higher molecular weight isoforms induced predominantly in cancer. The addition of extra domains within the fibronectin type III repeat domain greatly affects TNC function with multiple exon combinations available for splicing. Exons 14 and 16 are considered to be tumour-associated and have been shown to affect breast cell line invasion and growth in vitro to a greater extent than the full-length TNC isoform. This mini review will provide a summary of the literature to date regarding the expression of TNC isoforms in the breast and also discuss more recent developments in the field regarding exon AD1.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20814719     DOI: 10.1007/s10555-010-9249-9

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  22 in total

Review 1.  Targeting tumor cell motility to prevent metastasis.

Authors:  Trenis D Palmer; William J Ashby; John D Lewis; Andries Zijlstra
Journal:  Adv Drug Deliv Rev       Date:  2011-06-02       Impact factor: 15.470

2.  Cancer cell invasion driven by extracellular matrix remodeling is dependent on the properties of cancer-associated fibroblasts.

Authors:  Shinya Neri; Hiroko Hashimoto; Hiroaki Kii; Hirotada Watanabe; Kenkichi Masutomi; Takeshi Kuwata; Hiroshi Date; Masahiro Tsuboi; Koichi Goto; Atsushi Ochiai; Genichiro Ishii
Journal:  J Cancer Res Clin Oncol       Date:  2015-09-15       Impact factor: 4.553

Review 3.  Stromal biomarkers in breast cancer development and progression.

Authors:  Jenny A Rudnick; Charlotte Kuperwasser
Journal:  Clin Exp Metastasis       Date:  2012-06-10       Impact factor: 5.150

4.  Clinical significance of serum tenascin-c levels in epithelial ovarian cancer.

Authors:  Tastekin Didem; Tas Faruk; Karabulut Senem; Duranyildiz Derya; Serilmez Murat; Guveli Murat; Kaynur Oznur
Journal:  Tumour Biol       Date:  2014-04-11

Review 5.  Breast tumor and stromal cell responses to TGF-β and hypoxia in matrix deposition.

Authors:  Colleen S Curran; Patricia J Keely
Journal:  Matrix Biol       Date:  2012-12-20       Impact factor: 11.583

6.  Clinical significance of serum tenascin-C levels in breast cancer.

Authors:  D Tastekin; F Tas; S Karabulut; D Duranyildiz; M Serilmez; M Guveli; S Vatansever
Journal:  Tumour Biol       Date:  2014-04-03

Review 7.  Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles.

Authors:  Jenny G Parvani; Mark W Jackson
Journal:  Endocr Relat Cancer       Date:  2017-02-01       Impact factor: 5.900

8.  RNA sequencing of cancer reveals novel splicing alterations.

Authors:  Jeyanthy Eswaran; Anelia Horvath; Sucheta Godbole; Sirigiri Divijendra Reddy; Prakriti Mudvari; Kazufumi Ohshiro; Dinesh Cyanam; Sujit Nair; Suzanne A W Fuqua; Kornelia Polyak; Liliana D Florea; Rakesh Kumar
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

9.  Tenascin-W is a better cancer biomarker than tenascin-C for most human solid tumors.

Authors:  Florence Brellier; Enrico Martina; Martin Degen; Nathalie Heuzé-Vourc'h; Agnès Petit; Thomas Kryza; Yves Courty; Luigi Terracciano; Christian Ruiz; Ruth Chiquet-Ehrismann
Journal:  BMC Clin Pathol       Date:  2012-09-04

Review 10.  Why the stroma matters in breast cancer: insights into breast cancer patient outcomes through the examination of stromal biomarkers.

Authors:  Matthew W Conklin; Patricia J Keely
Journal:  Cell Adh Migr       Date:  2012-05-01       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.